Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-14
2006-11-14
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S323000, C544S324000
Reexamination Certificate
active
07135477
ABSTRACT:
Disclosed are compounds which bind α4integrins, preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by α4integrins, preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
REFERENCES:
patent: 4018913 (1977-04-01), Okamoto et al.
patent: 4018915 (1977-04-01), Okamoto et al.
patent: 4036955 (1977-07-01), Okamoto et al.
patent: 4041156 (1977-08-01), Okamoto et al.
patent: 4046876 (1977-09-01), Okamoto et al.
patent: 4055636 (1977-10-01), Okamoto et al.
patent: 4055651 (1977-10-01), Okamoto et al.
patent: 4070457 (1978-01-01), Okamoto et al.
patent: 4073914 (1978-02-01), Kikumoto et al.
patent: 4085057 (1978-04-01), Masuda et al.
patent: 4096255 (1978-06-01), Kikumoto et al.
patent: 4104392 (1978-08-01), Okamoto et al.
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4438122 (1984-03-01), Holmwood et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4505910 (1985-03-01), Bagli
patent: 4518600 (1985-05-01), Holmwood et al.
patent: 4544402 (1985-10-01), Schnurbusch et al.
patent: 4559345 (1985-12-01), Gomarasca et al.
patent: 4672065 (1987-06-01), Spatz
patent: 4837028 (1989-06-01), Allen
patent: 4908368 (1990-03-01), Murase et al.
patent: 4959364 (1990-09-01), Mueller et al.
patent: 4992439 (1991-02-01), Meanwell
patent: 5023252 (1991-06-01), Hseih et al.
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5120734 (1992-06-01), Klausener et al.
patent: 5238934 (1993-08-01), Knüppel et al.
patent: 5278184 (1994-01-01), Artico et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5580868 (1996-12-01), Lunkenheimer et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5814643 (1998-09-01), Duggan et al.
patent: 5861429 (1999-01-01), Sato et al.
patent: 5925644 (1999-07-01), Jakobi et al.
patent: 5942504 (1999-08-01), Grobelny
patent: 5955491 (1999-09-01), Sohda et al.
patent: 5962479 (1999-10-01), Chen
patent: 5972946 (1999-10-01), Murata et al.
patent: 6005117 (1999-12-01), Wehner et al.
patent: 6492372 (2002-12-01), Konradi et al.
patent: 2655636 (1977-06-01), None
patent: 19536891 (1997-04-01), None
patent: 19713000 (1998-01-01), None
patent: 0116494 (1988-01-01), None
patent: 0526348 (1988-02-01), None
patent: 0288176 (1988-10-01), None
patent: 0330506 (1989-08-01), None
patent: 0147211 (1990-12-01), None
patent: 0535521 (1993-07-01), None
patent: HU169926 (1977-02-01), None
patent: 59212480 (1984-01-01), None
patent: WO 91/05038 (1991-04-01), None
patent: WO 92/16549 (1992-10-01), None
patent: WO 93/12809 (1993-07-01), None
patent: WO 96/01644 (1996-01-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 96/32383 (1996-10-01), None
patent: WO 97/23451 (1997-07-01), None
patent: WO 97/48726 (1997-12-01), None
patent: WO 98/00395 (1998-01-01), None
patent: WO 98/22430 (1998-05-01), None
patent: WO 98/33783 (1998-08-01), None
patent: WO 98/53814 (1998-12-01), None
patent: WO 98/53817 (1998-12-01), None
patent: WO 99/06390 (1999-02-01), None
patent: WO 99/06391 (1999-02-01), None
patent: WO 99/06431 (1999-02-01), None
patent: WO 99/06432 (1999-02-01), None
patent: WO 99/06433 (1999-02-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 99/10313 (1999-03-01), None
patent: WO 99/37605 (1999-07-01), None
patent: WO 99/37618 (1999-07-01), None
patent: WO 99/52898 (1999-10-01), None
patent: WO 00/18759 (2000-04-01), None
patent: WO 00/31067 (2000-06-01), None
patent: WO 00/43369 (2000-07-01), None
patent: WO 02/08201 (2002-01-01), None
Tarkowski et al. Int. Arch. Allergy Immunol. 121(1) 25-33, 2000.
Piraino, P.S. et al., “Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of α4 integrin,”Journal of Neuroimmunology, 131:147-159 (2002).
Miller, S. D., et al., “Colloquium C15: Comparison of the ability of anit-VLA-4 antibody and a small molecule VLA-4 antagonist to regulate ongoing relapsing EAE,”Journal of Neurochemistry, C15-02,85: (Suppl.1) (2003).
Miller, D.H., “Colloquium C15:Natalizumab (anti-VLA4 antibody) in multiple sclerosis,”Journal of Neurochemistry, C15-04, 85: (Suppl. 1) (2003).
Sandborn, et al., “Biologic Therapy of Inflammatory Bowel Disease,”Gastroenterology, 122:1592-1608 (2002).
Tilley et al., “VLA-4 antagonists,”Drugs of the Future, 26(10):289-998 (2001).
Elices et al., “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distince from the VLA-4/Fibronectin Binding Site”Cell60:577-584 (1990).
Springer, Timothy A., “Adhesion receptors of the immune system”Nature346:425-434 (1990).
Osborne, Laurelee, “Leukocyte Adhesion to Endothelium in Inflammation”Cell62:3-6 (1990).
Vedder et al., “Role of neutrophils in generalized reperfusion injury associated with resuscitation from shock”Surgery106:509-516 (1989).
Pretolani et al., “Antibody to Very Late Activation Antigen 4 Prevents Antigen-induced bronchial Hyperreactivity and Cellular Infiltration in the Guinea Pig Airways”J. Exp. Med.180:795-805 (1994).
Abraham et al., “α4-Integrins Mediate Antigen-induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep”J. Clin. Invest.93:776787 (1994).
Mulligan et al., “Role of β1, β2Integrins and ICAM-1 in Lung Injury after Deposition of IgG and Iga Immune Complexes”J. Immunology150:2407-2417 (1993).
Cybulsky et al. “Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule During Atherogenesis”Science251:788-791 (1991).
Li et al. “An Atherogenic Diet Rapidly Induces VCAM-1, a Cytokine-Regulatable Mononuclear Leukocyte Adhesion Molecule, in Rabbit Aortic Endothelium”Arterioscler. Thromb13:197-204 (1993).
Sasseville et al. “Monocyte Adhesion to Endothelium in Simian Immunodeficiency Virus-Induced AIDS Encephalitis is Mediated by Vascular Cell Adhesion Molecule-1/a4α1 Integrin Interactions”Am. J. Path.144:27-40 (1994).
Yang et al “Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors”Proc. Nat. Acad. Science(USA) 90:10494-10498 (1993).
Burkly et al. “Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigen-4 Integrin”Diabetes43:529-534 (1994).
Baron et al. “The Pathogenesis of Adoptive Murine Autoimmune Diabetes Requires an Interaction between α 4-Integrins and Vascular Cell Adhesion Molecule”J. Clin. Invest., 93:1700-1708 (1994).
Hamann et al. “Role of α4-Integrins in Lymphocyte Homing to Muscosal Tissues in Vivo”Immunology, 152:3282-3293 (1994).
Yednock et al. “Prevention of experimental autoiummune encephalomyelitis by antibodies against α4β integrin”Nature356:63 (1992).
Baron et al. “Surface Expression of α4 Integrin by CD4 T Cells Is Required for Their Entry into Brain Parenchyma”J. Exp. Med.177:57-68 (1993).
vanDinther-Janssen et al. “The VLA-4/VCAM-1 Pathway is Involved in Lymphocyte Adhesion to Endothelium in rheumatoid Synovium”J. Immunology, 147-4207-4210 (1991).
vanDinther-Janssen et al. “Role of the CS1 adhesion motif of fibronectin in T cell adhesion to synovial membrane and peripheral lymph node endothelium”Annals. Rheumatic Dis., 52:672-676 (1993).
Elices et al. “Expression and Functional Significance of Alternatively Spliced CS1 Fibronectin in Rheumatoid Arthritis Microvasculature”J. Clin. Invest.93:405-416 (1994).
Postigo et al. “Increa
Konradi Andrei W.
Pleiss Michael A.
Semko Christopher M.
Smith Jenifer
Stappenbeck Frank
Balasubramanian Venkataraman
Elan Pharmaceuticals Inc.
Foley & Lardner LLP
LandOfFree
Heterocyclic compounds which inhibit leukocyte adhesion... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds which inhibit leukocyte adhesion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds which inhibit leukocyte adhesion... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3669380